Организационные риски современной антихеликобактерной терапии

С. Ю. Сереброва, А. Б. Прокофьев, В Н Дроздов et al. · Экспериментальная и клиническая гастроэнтерология · 2019

Aim: The aim of this work is to assess the organizational risks of H. pylori eradication therapy and the control methods of antibiotic resistance by a clinico-pharmacological analysis of the purchases structure in Russian state-funded medical facilities. Materials and methods: A legal framework in the fields of purchases of products, works, services for state and municipal needs, open contract bids, schedule and annual procurement plans for 2017, the Ministry of Health of Russian Federation statistical materials were explored. Results: According to Russian and international guidelines, current purchases of products, works, services are mainly related to a primary H. pylori identification not its eradication control. “Quasi-reference” H. pylori diagnostic methods with lower sensitivity in comparison to reference ones and extremely low specificity are relatively popular. Conclusion: Information related to the structure of products, works and services purchases for H. pylori diagnostics on the Federal Acts No. 44 and 223 united information web-system (http://zakupki.gov.ru) shows no rational assessment of effective eradication therapy while H. pylori is recognized as a microorganism with a high potential for adverse drug reactions and drug-to-drug adverse interactions development. WHO made H. pylori a priority pathogen for antibiotics research and development.

Cited by 1 works. doi:10.31146/1682-8658-ecg-166-6-29-36

Authors